« Cancer Cells: Too Unstable For Fine Targeting? |
| Avastin: Taking It Back »
August 16, 2010
Is Genzyme a Buyable Company At All?
Word is now that Genzyme's manufacturing problems won't be solved for years, which has people wondering if Sanofi-Aventis (or anyone) will feel safe making a bid for them. That's the single biggest issue hanging over the company, and that's an awful lot of uncertainly to be taking on.
If so, it looks more and more like whoever set up this trade will end up doing just fine on it. . .
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- The Worst Seminar
- Conference in Basel
- Messed-Up Clinical Studies: A First-Hand Report
- Pharma and Ebola
- Lilly Steps In for AstraZeneca's Secretase Inhibitor
- Update on Alnylam (And the Direction of Things to Come)
- There Must Have Been Multiple Chances to Catch This
- Weirdly, Tramadol Is Not a Natural Product After All